Earnest Partners LLC Sells 27,310 Shares of Hologic, Inc. $HOLX

Key Points

• Earnest Partners LLC reduced its holdings in Hologic, Inc. by 1.4% during the first quarter, now owning approximately 1,867,788 shares valued at $115,373,000 after selling 27,310 shares.
• Hologic reported a $1.08 EPS for the latest quarter, exceeding the consensus estimate of $1.05, with revenue rising 1.2% year-over-year to $1.02 billion.
• Analysts have mixed ratings for Hologic, with one giving a Strong Buy, eight a Buy, and eight a Hold rating, resulting in an average target price of $78.00.

Earnest Partners LLC reduced its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 1.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,867,788 shares of the medical equipment provider's stock after selling 27,310 shares during the period. Earnest Partners LLC owned approximately 0.84% of Hologic worth $115,373,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Zions Bancorporation National Association UT acquired a new position in Hologic in the first quarter valued at approximately $34,000. Allworth Financial LP lifted its holdings in Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after buying an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Hologic in the first quarter valued at approximately $42,000. Larson Financial Group LLC lifted its holdings in Hologic by 6,016.7% in the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 722 shares during the period. Finally, Raiffeisen Bank International AG acquired a new position in Hologic in the fourth quarter valued at approximately $49,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Up 0.8%

Shares of HOLX stock traded up $0.50 during trading hours on Monday, hitting $67.12. 1,080,191 shares of the company were exchanged, compared to its average volume of 1,681,669. The business has a 50 day moving average of $66.15 and a two-hundred day moving average of $62.49. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The company has a market capitalization of $14.93 billion, a PE ratio of 27.85, a PEG ratio of 2.44 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the firm earned $1.06 earnings per share. The firm's revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on HOLX shares. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and upped their target price for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Mizuho set a $75.00 target price on shares of Hologic in a research note on Thursday, July 31st. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and upped their target price for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Stephens lowered their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Finally, Morgan Stanley upped their target price on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.